{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:07:48Z","timestamp":1793423268947,"version":"4.5.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"DOI":"10.1038\/s44161-026-00804-8","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:04:32Z","timestamp":1776157472000},"page":"291-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["mRNA medicine for cardiovascular disease"],"prefix":"10.1038","volume":"5","author":[{"given":"Zhuoming","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-0252","authenticated-orcid":false,"given":"Haojie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Tabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-4618","authenticated-orcid":false,"given":"Roger SY","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-3728","authenticated-orcid":false,"given":"Wei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"804_CR1","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz, H., Atochina-Vasserman, E. N. & Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403, 1192\u20131204 (2024).","journal-title":"Lancet"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","volume":"28","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. The landscape of mRNA nanomedicine. Nat. Med. 28, 2273\u20132287 (2022). This review provides an overview of the advancements and innovations in mRNA nanomedicine, focusing on mRNA delivery systems and their clinical translation.","journal-title":"Nat. Med."},{"key":"804_CR3","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"804_CR4","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah, G. A., Fuster, V., Murray, C. J. L. & Roth, G. A. Global burden of cardiovascular diseases and risks, 1990\u20132022. J. Am. Coll. Cardiol. 82, 2350\u20132473 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"804_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","volume":"67","author":"RC Hoogeveen","year":"2021","unstructured":"Hoogeveen, R. C. & Ballantyne, C. M. Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation. Clin. Chem. 67, 143\u2013153 (2021).","journal-title":"Clin. Chem."},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth, G. A. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982\u20133021 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"804_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526\u2013543 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"804_CR8","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1039\/D1CS00617G","volume":"51","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y. et al. Emerging mRNA technologies: delivery strategies and biomedical applications. Chem. Soc. Rev. 51, 3828\u20133845 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"804_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s43586-023-00246-7","volume":"3","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Methods Primers 3, 63 (2023).","journal-title":"Nat. Rev. Methods Primers"},{"key":"804_CR10","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.medj.2024.11.015","volume":"6","author":"A Yaremenko","year":"2025","unstructured":"Yaremenko, A. et al. Clinical advances of mRNA vaccines for cancer immunotherapy. Med 6, 100562 (2025).","journal-title":"Med"},{"key":"804_CR11","doi-asserted-by":"publisher","unstructured":"Liu, C. et al. mRNA technology for the prevention and treatment of HIV-1 infection. Nat. Rev. Bioeng. https:\/\/doi.org\/10.1038\/s44222-025-00387-2 (2026).","DOI":"10.1038\/s44222-025-00387-2"},{"key":"804_CR12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases - advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"804_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6 mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"804_CR14","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1016\/j.cell.2025.05.032","volume":"188","author":"M B\u00e9routi","year":"2025","unstructured":"B\u00e9routi, M. et al. Pseudouridine RNA avoids immune detection through impaired endolysosomal processing and TLR engagement. Cell 188, 4880\u20134895 (2025).","journal-title":"Cell"},{"key":"804_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005). This work reveals that nucleoside modifications can reduce the potential of RNA to activate TLR-mediated immune responses.","journal-title":"Immunity"},{"key":"804_CR16","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"804_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","volume":"23","author":"M Metkar","year":"2024","unstructured":"Metkar, M., Pepin, C. S. & Moore, M. J. Tailor made: the art of therapeutic mRNA design. Nat. Rev. Drug Discov. 23, 67\u201383 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"804_CR18","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1002\/cpz1.39","volume":"1","author":"JM Henderson","year":"2021","unstructured":"Henderson, J. M. et al. Cap 1 messenger RNA synthesis with co-transcriptional CleanCap analog by in vitro transcription. Curr. Protoc. 1, e39 (2021).","journal-title":"Curr. Protoc."},{"key":"804_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"804_CR20","doi-asserted-by":"crossref","unstructured":"Ascanelli, C., Lawrence, E., Batho, C. A. P. & Wilson, C. H. A flexible, high-throughput system for studying live mRNA translation with HiBiT technology. Nucleic Acids Res. 53, gkaf496 (2025).","DOI":"10.1093\/nar\/gkaf496"},{"key":"804_CR21","doi-asserted-by":"publisher","first-page":"10708","DOI":"10.1073\/pnas.1408677111","volume":"111","author":"DY Kim","year":"2014","unstructured":"Kim, D. Y. et al. Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs. Proc. Natl Acad. Sci. USA 111, 10708\u201310713 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"804_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s44258-026-00079-5","volume":"4","author":"X Zhen","year":"2026","unstructured":"Zhen, X. et al. Unlocking the potential of engineered circular RNA therapeutics. Med-X 4, 7 (2026).","journal-title":"Med-X"},{"key":"804_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710\u2013728 (2019).","journal-title":"Mol. Ther."},{"key":"804_CR24","doi-asserted-by":"publisher","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","volume":"2","author":"KA Hajj","year":"2017","unstructured":"Hajj, K. A. & Whitehead, K. A. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater. 2, 17056 (2017).","journal-title":"Nat. Rev. Mater."},{"key":"804_CR25","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"804_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s44161-023-00232-y","volume":"2","author":"BR Smith","year":"2023","unstructured":"Smith, B. R. & Edelman, E. R. Nanomedicines for cardiovascular disease. Nat. Cardiovasc. Res. 2, 351\u2013367 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"804_CR27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709\u2013722 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"804_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41569-021-00669-3","volume":"19","author":"M Nishiga","year":"2022","unstructured":"Nishiga, M., Liu, C., Qi, L. S. & Wu, J. C. The use of new CRISPR tools in cardiovascular research and medicine. Nat. Rev. Cardiol. 19, 505\u2013521 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"804_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186\u2013191 (2015).","journal-title":"Nature"},{"key":"804_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249\u2013254 (2019).","journal-title":"Nat. Med."},{"key":"804_CR31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41573-023-00762-x","volume":"22","author":"V Madigan","year":"2023","unstructured":"Madigan, V., Zhang, F. & Dahlman, J. E. Drug delivery systems for CRISPR-based genome editors. Nat. Rev. Drug Discov. 22, 875\u2013894 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"804_CR32","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","volume":"35","author":"H Yin","year":"2017","unstructured":"Yin, H. et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179\u20131187 (2017).","journal-title":"Nat. Biotechnol."},{"key":"804_CR33","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06164730 (2024)."},{"key":"804_CR34","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06451770 (2024)."},{"key":"804_CR35","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05398029 (2022)."},{"key":"804_CR36","first-page":"A17013","volume":"148","author":"PK Morrow","year":"2023","unstructured":"Morrow, P. K. et al. Abstract 17013: CTX320: an investigational in vivo CRISPR-based therapy efficiently and durably reduces lipoprotein (a) levels in non-human primates after a single dose. Circulation 148, A17013\u2013A17013 (2023).","journal-title":"Circulation"},{"key":"804_CR37","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","volume":"391","author":"M Fontana","year":"2024","unstructured":"Fontana, M. et al. CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy. N. Engl. J. Med. 391, 2231\u20132241 (2024). This trial reports that a single dose of mRNA-encoded CRISPR therapy, nexiguran ziclumeran, results in rapid and durable reductions in serum TTR levels, showing promise for the treatment of ATTR-CM.","journal-title":"N. Engl. J. Med."},{"key":"804_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"804_CR39","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41587-024-02320-1","volume":"42","author":"SR McCutcheon","year":"2024","unstructured":"McCutcheon, S. R., Rohm, D., Iglesias, N. & Gersbach, C. A. Epigenome editing technologies for discovery and medicine. Nat. Biotechnol. 42, 1199\u20131217 (2024).","journal-title":"Nat. Biotechnol."},{"key":"804_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-024-07087-8","volume":"627","author":"MA Cappelluti","year":"2024","unstructured":"Cappelluti, M. A. et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature 627, 416\u2013423 (2024). This study shows that liver-specific delivery of mRNAs encoding engineered zinc-finger protein-based transcriptional repressors via LNPs achieves durable epigenetic silencing of Pcsk9 in mice.","journal-title":"Nature"},{"key":"804_CR41","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41591-025-03508-x","volume":"31","author":"F Tremblay","year":"2025","unstructured":"Tremblay, F. et al. A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels. Nat. Med. 31, 1329\u20131338 (2025).","journal-title":"Nat. Med."},{"key":"804_CR42","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41569-025-01143-0","volume":"22","author":"L Chiapperino","year":"2025","unstructured":"Chiapperino, L., Habets, M. & Paneni, F. Epigenetic editing in cardiovascular medicine: moving beyond the hype. Nat. Rev. Cardiol. 22, 389\u2013390 (2025).","journal-title":"Nat. Rev. Cardiol."},{"key":"804_CR43","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N., Maus, M. V. & Hinrichs, C. S. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA 332, 1924\u20131935 (2024).","journal-title":"JAMA"},{"key":"804_CR44","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","volume":"8","author":"A Taraseviciute","year":"2018","unstructured":"Taraseviciute, A. et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 8, 750\u2013763 (2018).","journal-title":"Cancer Discov."},{"key":"804_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.tibtech.2024.07.012","volume":"43","author":"Y He","year":"2025","unstructured":"He, Y., Johnston, A. P. R. & Pouton, C. W. Therapeutic applications of cell engineering using mRNA technology. Trends Biotechnol. 43, 83\u201397 (2025).","journal-title":"Trends Biotechnol."},{"key":"804_CR46","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"804_CR47","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. 393, 1542\u20131544 (2025).","journal-title":"N. Engl. J. Med."},{"key":"804_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022). This study presents an mRNA-engineered anti-fibrotic CAR-T platform that enables the transient reprogramming of T cells to selectively deplete activated cardiac fibroblasts for treating cardiac fibrosis.","journal-title":"Science"},{"key":"804_CR49","doi-asserted-by":"publisher","first-page":"e2417831","DOI":"10.1002\/adma.202417831","volume":"37","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. Legumain in situ engineering promotes efferocytosis of CAR macrophage to treat cardiac fibrosis. Adv. Mater. 37, e2417831 (2025).","journal-title":"Adv. Mater."},{"key":"804_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59093-7","volume":"16","author":"J Yan","year":"2025","unstructured":"Yan, J. et al. Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile. Nat. Commun. 16, 3748 (2025).","journal-title":"Nat. Commun."},{"key":"804_CR51","doi-asserted-by":"publisher","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","volume":"3","author":"JC Defesche","year":"2017","unstructured":"Defesche, J. C. et al. Familial hypercholesterolaemia. Nat. Rev. Dis. Primers 3, 17093 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"804_CR52","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1161\/ATVBAHA.122.317963","volume":"43","author":"RF Oostveen","year":"2023","unstructured":"Oostveen, R. F. et al. New approaches for targeting PCSK9: small-interfering ribonucleic acid and genome editing. Arterioscler. Thromb. Vasc. Biol. 43, 1081\u20131092 (2023).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"804_CR53","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee, R. G. et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation 147, 242\u2013253 (2023).","journal-title":"Circulation"},{"key":"804_CR54","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429\u2013434 (2021). This study demonstrates that mRNA-encoded CRISPR base editing of PCSK9 efficiently and durably reduces LDL-C levels in NHPs.","journal-title":"Nature"},{"key":"804_CR55","unstructured":"Verve Therapeutics. Verve Therapeutics announces updates on its PCSK9 program. https:\/\/vervetx.gcs-web.com\/news-releases\/news-release-details\/verve-therapeutics-announces-updates-its-pcsk9-program\/ (2024)."},{"key":"804_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11883-024-01269-5","volume":"27","author":"DJ Blom","year":"2025","unstructured":"Blom, D. J., Marais, A. D. & Raal, F. J. Homozygous familial hypercholesterolemia treatment: new developments. Curr. Atheroscler. Rep. 27, 22 (2025).","journal-title":"Curr. Atheroscler. Rep."},{"key":"804_CR57","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/ATVBAHA.122.317966","volume":"43","author":"HN Ginsberg","year":"2023","unstructured":"Ginsberg, H. N. & Goldberg, I. J. Broadening the scope of dyslipidemia therapy by targeting APOC3 (apolipoprotein C3) and ANGPTL3 (angiopoietin-like protein 3). Arterioscler. Thromb. Vasc. Biol. 43, 388\u2013398 (2023).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"804_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37465-1","volume":"14","author":"LN Kasiewicz","year":"2023","unstructured":"Kasiewicz, L. N. et al. GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nat. Commun. 14, 2776 (2023).","journal-title":"Nat. Commun."},{"key":"804_CR59","doi-asserted-by":"publisher","first-page":"17721","DOI":"10.1021\/acsnano.3c00958","volume":"17","author":"M Gao","year":"2023","unstructured":"Gao, M. et al. Modulating plaque inflammation via targeted mRNA nanoparticles for the treatment of atherosclerosis. ACS Nano 17, 17721\u201317739 (2023).","journal-title":"ACS Nano"},{"key":"804_CR60","doi-asserted-by":"publisher","first-page":"9988","DOI":"10.7150\/thno.64229","volume":"11","author":"T Bu","year":"2021","unstructured":"Bu, T. et al. Exosome-mediated delivery of inflammation-responsive Il-10 mRNA for controlled atherosclerosis treatment. Theranostics 11, 9988\u201310000 (2021).","journal-title":"Theranostics"},{"key":"804_CR61","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.7150\/thno.82873","volume":"13","author":"Z Yang","year":"2023","unstructured":"Yang, Z. et al. Improved extracellular vesicle-based mRNA delivery for familial hypercholesterolemia treatment. Theranostics 13, 3467\u20133479 (2023).","journal-title":"Theranostics"},{"key":"804_CR62","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.7150\/thno.49874","volume":"11","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model. Theranostics 11, 2953\u20132965 (2021).","journal-title":"Theranostics"},{"key":"804_CR63","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05043181 (2021)."},{"key":"804_CR64","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1161\/01.CIR.103.9.1274","volume":"103","author":"K Oka","year":"2001","unstructured":"Oka, K. et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 103, 1274\u20131281 (2001).","journal-title":"Circulation"},{"key":"804_CR65","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.jacc.2024.02.056","volume":"83","author":"FGP Welt","year":"2024","unstructured":"Welt, F. G. P. et al. Reperfusion injury in patients with acute myocardial infarction: JACC Scientific Statement. J. Am. Coll. Cardiol. 83, 2196\u20132213 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"804_CR66","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jchf.2024.04.025","volume":"12","author":"J Carberry","year":"2024","unstructured":"Carberry, J., Marquis-Gravel, G., O\u2019Meara, E. & Docherty, K. F. Where are we with treatment and prevention of heart failure in patients post-myocardial infarction?. JACC Heart Fail. 12, 1157\u20131165 (2024).","journal-title":"JACC Heart Fail."},{"key":"804_CR67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","volume":"27","author":"A Magadum","year":"2019","unstructured":"Magadum, A., Kaur, K. & Zangi, L. mRNA-based protein replacement therapy for the heart. Mol. Ther. 27, 785\u2013793 (2019).","journal-title":"Mol. Ther."},{"key":"804_CR68","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/nbt.2682","volume":"31","author":"L Zangi","year":"2013","unstructured":"Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31, 898\u2013907 (2013). This work reports that intramyocardial injection of VEGFA mRNA can enhance progenitor cell differentiation, promote vascular regeneration and improve heart function after myocardial infarction.","journal-title":"Nat. Biotechnol."},{"key":"804_CR69","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.omtm.2018.04.003","volume":"9","author":"L Carlsson","year":"2018","unstructured":"Carlsson, L. et al. Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine. Mol. Ther. Methods Clin. Dev. 9, 330\u2013346 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"804_CR70","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/eurheartj\/ehae883","volume":"46","author":"Y You","year":"2025","unstructured":"You, Y. et al. Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity. Eur. Heart J. 46, 1662\u20131676 (2025).","journal-title":"Eur. Heart J."},{"key":"804_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08852-4","volume":"10","author":"LM Gan","year":"2019","unstructured":"Gan, L. M. et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nat. Commun. 10, 871 (2019).","journal-title":"Nat. Commun."},{"key":"804_CR72","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","volume":"18","author":"V Anttila","year":"2020","unstructured":"Anttila, V. et al. Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial. Mol. Ther. Methods Clin. Dev. 18, 464\u2013472 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"804_CR73","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","volume":"31","author":"V Anttila","year":"2023","unstructured":"Anttila, V. et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol. Ther. 31, 866\u2013874 (2023). The first clinical trial of intramyocardial injection of naked VEGFA mRNA (AZD8601) in patients undergoing CABG, showing promising safety and tolerability.","journal-title":"Mol. Ther."},{"key":"804_CR74","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.119.041882","volume":"141","author":"Y Hadas","year":"2020","unstructured":"Hadas, Y. et al. Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction. Circulation 141, 916\u2013930 (2020).","journal-title":"Circulation"},{"key":"804_CR75","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.119.043067","volume":"141","author":"A Magadum","year":"2020","unstructured":"Magadum, A. et al. Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration. Circulation 141, 1249\u20131265 (2020).","journal-title":"Circulation"},{"key":"804_CR76","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCRESAHA.123.322929","volume":"133","author":"J Sun","year":"2023","unstructured":"Sun, J. et al. CCND2 modified mRNA activates cell cycle of cardiomyocytes in hearts with myocardial infarction in mice and pigs. Circ. Res. 133, 484\u2013504 (2023).","journal-title":"Circ. Res."},{"key":"804_CR77","doi-asserted-by":"publisher","unstructured":"Boikova, A. et al. A transient modified mRNA encoding Myc and Cyclin T1 induces cardiac regeneration and improves cardiac function after myocardial injury. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.08.02.551469 (2023).","DOI":"10.1101\/2023.08.02.551469"},{"key":"804_CR78","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","volume":"43","author":"S Frantz","year":"2022","unstructured":"Frantz, S., Hundertmark, M. J., Schulz-Menger, J., Bengel, F. M. & Bauersachs, J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur. Heart J. 43, 2549\u20132561 (2022).","journal-title":"Eur. Heart J."},{"key":"804_CR79","doi-asserted-by":"crossref","unstructured":"Travers, J. G., Tharp, C. A., Rubino, M. & McKinsey, T. A. Therapeutic targets for cardiac fibrosis: from old school to next-gen. J. Clin. Invest. 132, e148554 (2022).","DOI":"10.1172\/JCI148554"},{"key":"804_CR80","doi-asserted-by":"publisher","first-page":"2004661","DOI":"10.1002\/advs.202004661","volume":"8","author":"A Magadum","year":"2021","unstructured":"Magadum, A. et al. Therapeutic delivery of Pip4k2c-modified mRNA attenuates cardiac hypertrophy and fibrosis in the failing heart. Adv. Sci. 8, 2004661 (2021).","journal-title":"Adv. Sci."},{"key":"804_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56703-2","volume":"16","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. CD248-targeted BBIR-T cell therapy against late-activated fibroblasts in cardiac repair after myocardial infarction. Nat. Commun. 16, 2895 (2025).","journal-title":"Nat. Commun."},{"key":"804_CR82","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s44161-025-00617-1","volume":"4","author":"G Li","year":"2025","unstructured":"Li, G. et al. Dynamic molecular atlas of cardiac fibrosis at single-cell resolution shows CD248 in cardiac fibroblasts orchestrates interactions with immune cells. Nat. Cardiovasc. Res. 4, 380\u2013396 (2025).","journal-title":"Nat. Cardiovasc. Res."},{"key":"804_CR83","doi-asserted-by":"publisher","first-page":"e013465","DOI":"10.1161\/JAHA.119.013465","volume":"8","author":"J Sun","year":"2019","unstructured":"Sun, J. et al. Human relaxin-2 fusion protein treatment prevents and reverses isoproterenol-induced hypertrophy and fibrosis in mouse heart. J. Am. Heart. Assoc. 8, e013465 (2019).","journal-title":"J. Am. Heart. Assoc."},{"key":"804_CR84","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05659264 (2022)."},{"key":"804_CR85","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jacc.2024.01.010","volume":"83","author":"E Gonzalez-Lopez","year":"2024","unstructured":"Gonzalez-Lopez, E. et al. Histological typing in patients with cardiac amyloidosis: JACC review topic of the week. J. Am. Coll. Cardiol. 83, 1085\u20131099 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"804_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11\u201321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"804_CR87","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"key":"804_CR88","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05697861 (2023)."},{"key":"804_CR89","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06128629 (2023)."},{"key":"804_CR90","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41551-024-01211-9","volume":"8","author":"DW Wolfson","year":"2024","unstructured":"Wolfson, D. W. et al. Transient pacing in pigs with complete heart block via myocardial injection of mRNA coding for the T-box transcription factor 18. Nat. Biomed. Eng. 8, 1124\u20131141 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"804_CR91","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCULATIONAHA.124.072340","volume":"151","author":"Y Zou","year":"2025","unstructured":"Zou, Y. et al. Modified mRNA treatment restores cardiac function in desmocollin-2-deficient mouse models of arrhythmogenic right ventricular cardiomyopathy. Circulation 151, 1780\u20131796 (2025).","journal-title":"Circulation"},{"key":"804_CR92","doi-asserted-by":"crossref","unstructured":"Golombek, S. et al. A novel strategy for the treatment of aneurysms: inhibition of MMP-9 activity through the delivery of TIMP-1 encoding synthetic mRNA into arteries. Int. J. Mol. Sci. 25, 6599 (2024).","DOI":"10.3390\/ijms25126599"},{"key":"804_CR93","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.7150\/thno.104957","volume":"15","author":"H Yan","year":"2025","unstructured":"Yan, H. et al. Augmented expression of superoxide dismutase 2 mitigates progression and rupture of experimental abdominal aortic aneurysm. Theranostics 15, 4016\u20134032 (2025).","journal-title":"Theranostics"},{"key":"804_CR94","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian, A. J. & Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 121, 749\u2013770 (2017).","journal-title":"Circ. Res."},{"key":"804_CR95","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"804_CR96","doi-asserted-by":"publisher","first-page":"126847","DOI":"10.1016\/j.vaccine.2025.126847","volume":"50","author":"M Soens","year":"2025","unstructured":"Soens, M. et al. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine 50, 126847 (2025).","journal-title":"Vaccine"},{"key":"804_CR97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S1473-3099(24)00589-9","volume":"25","author":"J Goswami","year":"2025","unstructured":"Goswami, J. et al. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Lancet Infect. Dis. 25, 411\u2013423 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"804_CR98","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray, K. K. et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med. 382, 1507\u20131519 (2020).","journal-title":"N. Engl. J. Med."},{"key":"804_CR99","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai, A. S. et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N. Engl. J. Med. 389, 228\u2013238 (2023).","journal-title":"N. Engl. J. Med."},{"key":"804_CR100","doi-asserted-by":"crossref","unstructured":"Skerritt, J. H. Considerations for mRNA product development, regulation and deployment across the lifecycle. Vaccines 13, 473 (2025).","DOI":"10.3390\/vaccines13050473"},{"key":"804_CR101","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41569-020-00499-9","volume":"18","author":"S Sahoo","year":"2021","unstructured":"Sahoo, S., Kariya, T. & Ishikawa, K. Targeted delivery of therapeutic agents to the heart. Nat. Rev. Cardiol. 18, 389\u2013399 (2021). This review discusses the latest strategies for targeting and delivering therapeutic agents to the heart and how to translate cardiac gene therapy into the clinical setting.","journal-title":"Nat. Rev. Cardiol."},{"key":"804_CR102","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.jacc.2021.03.307","volume":"77","author":"D Marlevi","year":"2021","unstructured":"Marlevi, D. & Edelman, E. R. Vascular lesion-specific drug delivery systems: JACC state-of-the-art review. J. Am. Coll. Cardiol. 77, 2413\u20132431 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"804_CR103","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41596-021-00665-4","volume":"17","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages. Nat. Protoc. 17, 748\u2013780 (2022).","journal-title":"Nat. Protoc."},{"key":"804_CR104","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41569-024-01094-y","volume":"22","author":"Z Zhou","year":"2025","unstructured":"Zhou, Z., Chen, W., Cao, Y., Abdi, R. & Tao, W. Nanomedicine-based strategies for the treatment of vein graft disease. Nat. Rev. Cardiol. 22, 255\u2013272 (2025).","journal-title":"Nat. Rev. Cardiol."},{"key":"804_CR105","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41569-021-00629-x","volume":"19","author":"W Chen","year":"2022","unstructured":"Chen, W. et al. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat. Rev. Cardiol. 19, 228\u2013249 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"804_CR106","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/s41565-024-01687-1","volume":"19","author":"Z He","year":"2024","unstructured":"He, Z. et al. Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment. Nat. Nanotechnol. 19, 1386\u20131398 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"804_CR107","doi-asserted-by":"publisher","first-page":"275ra220","DOI":"10.1126\/scitranslmed.aaa1065","volume":"7","author":"G Fredman","year":"2015","unstructured":"Fredman, G. et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med. 7, 275ra220 (2015).","journal-title":"Sci. Transl. Med."},{"key":"804_CR108","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.yjmcc.2011.02.003","volume":"50","author":"S Kanki","year":"2011","unstructured":"Kanki, S. et al. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J. Mol. Cell. Cardiol. 50, 841\u2013848 (2011).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"804_CR109","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jconrel.2024.04.018","volume":"369","author":"MCI Labonia","year":"2024","unstructured":"Labonia, M. C. I. et al. Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration. J. Control. Release 369, 734\u2013745 (2024).","journal-title":"J. Control. Release"},{"key":"804_CR110","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1161\/CIRCULATIONAHA.123.067097","volume":"149","author":"T Liu","year":"2024","unstructured":"Liu, T. et al. Advanced cardiac patches for the treatment of myocardial infarction. Circulation 149, 2002\u20132020 (2024).","journal-title":"Circulation"},{"key":"804_CR111","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cvr\/cvae207","volume":"120","author":"L Grisorio","year":"2024","unstructured":"Grisorio, L., Bongianino, R., Gianeselli, M. & Priori, S. G. Gene therapy for cardiac diseases: methods, challenges, and future directions. Cardiovasc. Res. 120, 1664\u20131682 (2024).","journal-title":"Cardiovasc. Res."},{"key":"804_CR112","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jacc.2023.10.029","volume":"83","author":"A Alogna","year":"2024","unstructured":"Alogna, A. et al. Lung-to-heart nano-in-micro peptide promotes cardiac recovery in a pig model of chronic heart failure. J. Am. Coll. Cardiol. 83, 47\u201359 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"804_CR113","doi-asserted-by":"crossref","unstructured":"Miragoli, M. et al. Inhalation of peptide-loaded nanoparticles improves heart failure. Sci. Transl. Med. 10, eaan6205 (2018).","DOI":"10.1126\/scitranslmed.aan6205"},{"key":"804_CR114","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"F Heil","year":"2004","unstructured":"Heil, F. et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303, 1526\u20131529 (2004).","journal-title":"Science"},{"key":"804_CR115","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1161\/ATVBAHA.110.220574","volume":"31","author":"N Maeda","year":"2011","unstructured":"Maeda, N. Development of apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31, 1957\u20131962 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"804_CR116","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1172\/JCI116663","volume":"92","author":"S Ishibashi","year":"1993","unstructured":"Ishibashi, S. et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883\u2013893 (1993).","journal-title":"J. Clin. Invest."},{"key":"804_CR117","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ame2.12010","volume":"1","author":"YP Tang","year":"2018","unstructured":"Tang, Y. P. et al. To develop a novel animal model of myocardial infarction: a research imperative. Animal Model. Exp. Med. 1, 36\u201339 (2018).","journal-title":"Animal Model. Exp. Med."},{"key":"804_CR118","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33, 941\u2013951 (2015).","journal-title":"Nat. Biotechnol."},{"key":"804_CR119","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1016\/S0021-9258(18)82232-3","volume":"268","author":"AM van den Maagdenberg","year":"1993","unstructured":"van den Maagdenberg, A. M. et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268, 10540\u201310545 (1993).","journal-title":"J. Biol. Chem."},{"key":"804_CR120","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1161\/CIRCRESAHA.125.326409","volume":"137","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. Novel mouse model of coronary atherosclerosis with myocardial infarction: insights into human CAD. Circ. Res. 137, e106\u2013e123 (2025).","journal-title":"Circ. Res."},{"key":"804_CR121","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41684-024-01377-4","volume":"53","author":"H Jia","year":"2024","unstructured":"Jia, H., Chang, Y. & Song, J. The pig as an optimal animal model for cardiovascular research. Lab Anim. 53, 136\u2013147 (2024).","journal-title":"Lab Anim."},{"key":"804_CR122","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jacbts.2020.04.011","volume":"5","author":"KAS Silva","year":"2020","unstructured":"Silva, K. A. S. & Emter, C. A. Large animal models of heart failure: a translational bridge to clinical success. JACC Basic Transl. Sci. 5, 840\u2013856 (2020).","journal-title":"JACC Basic Transl. Sci."},{"key":"804_CR123","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.jhlto.2025.100336","volume":"9","author":"JO Louca","year":"2025","unstructured":"Louca, J. O. et al. Ex situ heart perfusion: a novel platform to test cardiovascular therapeutics in human hearts. JHLT Open 9, 100336 (2025).","journal-title":"JHLT Open"},{"key":"804_CR124","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1161\/CIRCULATIONAHA.121.054317","volume":"145","author":"K Sallam","year":"2022","unstructured":"Sallam, K. et al. Modeling effects of immunosuppressive drugs on human hearts using induced pluripotent stem cell-derived cardiac organoids and single-cell RNA sequencing. Circulation 145, 1367\u20131369 (2022).","journal-title":"Circulation"},{"key":"804_CR125","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.addr.2018.06.007","volume":"140","author":"A Cochrane","year":"2019","unstructured":"Cochrane, A. et al. Advanced in vitro models of vascular biology: human induced pluripotent stem cells and organ-on-chip technology. Adv. Drug Deliv. Rev. 140, 68\u201377 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"804_CR126","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1093\/eurheartj\/ehae519","volume":"45","author":"X Wu","year":"2024","unstructured":"Wu, X. et al. Clinical trials in-a-dish for cardiovascular medicine. Eur. Heart J. 45, 4275\u20134290 (2024).","journal-title":"Eur. Heart J."},{"key":"804_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01282-y","volume":"16","author":"P Kiessling","year":"2024","unstructured":"Kiessling, P. & Kuppe, C. Spatial multi-omics: novel tools to study the complexity of cardiovascular diseases. Genome Med. 16, 14 (2024).","journal-title":"Genome Med."},{"key":"804_CR128","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s44161-022-00205-7","volume":"2","author":"WLW Tan","year":"2023","unstructured":"Tan, W. L. W. et al. Current and future perspectives of single-cell multi-omics technologies in cardiovascular research. Nat. Cardiovasc. Res. 2, 20\u201334 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"804_CR129","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.stem.2022.08.012","volume":"29","author":"M Sobecki","year":"2022","unstructured":"Sobecki, M. et al. Vaccination-based immunotherapy to target profibrotic cells in liver and lung. Cell Stem Cell 29, 1459\u20131474 (2022).","journal-title":"Cell Stem Cell"},{"key":"804_CR130","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCRESAHA.124.325017","volume":"136","author":"S Yoshida","year":"2025","unstructured":"Yoshida, S. et al. A vaccine against fibroblast activation protein improves murine cardiac fibrosis by preventing the accumulation of myofibroblasts. Circ. Res. 136, 26\u201340 (2025).","journal-title":"Circ. Res."},{"key":"804_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54059-7","volume":"15","author":"DP Cetnar","year":"2024","unstructured":"Cetnar, D. P., Hossain, A., Vezeau, G. E. & Salis, H. M. Predicting synthetic mRNA stability using massively parallel kinetic measurements, biophysical modeling, and machine learning. Nat. Commun. 15, 9601 (2024).","journal-title":"Nat. Commun."},{"key":"804_CR132","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","volume":"23","author":"B Li","year":"2024","unstructured":"Li, B. et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat. Mater. 23, 1002\u20131008 (2024).","journal-title":"Nat. Mater."},{"key":"804_CR133","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.jacc.2024.08.069","volume":"84","author":"JW Cunningham","year":"2024","unstructured":"Cunningham, J. W. et al. Artificial intelligence in cardiovascular clinical trials. J. Am. Coll. Cardiol. 84, 2051\u20132062 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"804_CR134","doi-asserted-by":"publisher","first-page":"e2020401118","DOI":"10.1073\/pnas.2020401118","volume":"118","author":"M Qiu","year":"2021","unstructured":"Qiu, M. et al. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3. Proc. Natl Acad. Sci. USA 118, e2020401118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"804_CR135","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1093\/eurheartj\/ehab547","volume":"42","author":"A Mojiri","year":"2021","unstructured":"Mojiri, A. et al. Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Eur. Heart J. 42, 4352\u20134369 (2021).","journal-title":"Eur. Heart J."},{"key":"804_CR136","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jconrel.2019.08.014","volume":"310","author":"Z Yu","year":"2019","unstructured":"Yu, Z. et al. Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia. J. Control. Release 310, 103\u2013114 (2019).","journal-title":"J. Control. Release"},{"key":"804_CR137","doi-asserted-by":"crossref","unstructured":"Chen, J. et al. aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model. Life Sci. Alliance 3, e201900424 (2020).","DOI":"10.26508\/lsa.201900424"},{"key":"804_CR138","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtn.2018.08.021","volume":"13","author":"A Magadum","year":"2018","unstructured":"Magadum, A. et al. Ablation of a single N-glycosylation site in human FSTL 1 induces cardiomyocyte proliferation and cardiac regeneration. Mol. Ther. Nucleic Acids 13, 133\u2013143 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"804_CR139","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.116.022064","volume":"135","author":"L Zangi","year":"2017","unstructured":"Zangi, L. et al. Insulin-like growth factor 1 receptor-dependent pathway drives epicardial adipose tissue formation after myocardial injury. Circulation 135, 59\u201372 (2017).","journal-title":"Circulation"},{"key":"804_CR140","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/CIRCRESAHA.125.326716","volume":"137","author":"H Du","year":"2025","unstructured":"Du, H. et al. CAR macrophages engineered in vivo for attenuating myocardial ischemia-reperfusion injury. Circ. Res. 137, 846\u2013859 (2025).","journal-title":"Circ. Res."},{"key":"804_CR141","doi-asserted-by":"crossref","unstructured":"Song, M. H. et al. Modified mRNA-mediated CCN5 gene transfer ameliorates cardiac dysfunction and fibrosis without adverse structural remodeling. Int. J. Mol. Sci. 25, 6262 (2024).","DOI":"10.3390\/ijms25116262"},{"key":"804_CR142","doi-asserted-by":"publisher","first-page":"e003293","DOI":"10.1161\/JAHA.112.003293","volume":"1","author":"O Zimmermann","year":"2012","unstructured":"Zimmermann, O. et al. Successful use of mRNA-nucleofection for overexpression of interleukin-10 in murine monocytes\/macrophages for anti-inflammatory therapy in a murine model of autoimmune myocarditis. J. Am. Heart Assoc. 1, e003293 (2012).","journal-title":"J. Am. Heart Assoc."},{"key":"804_CR143","first-page":"A16908","volume":"148","author":"PK Morrow","year":"2023","unstructured":"Morrow, P. K. et al. Abstract 16908: CTX310: an investigational in vivo CRISPR-based therapy efficiently and durably reduces ANGPTL3 protein and triglyceride levels in non-human primates after a single dose. Circulation 148, A16908\u2013A16908 (2023).","journal-title":"Circulation"},{"key":"804_CR144","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04601051 (2020)."},{"key":"804_CR145","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/190576a0","volume":"190","author":"S Brenner","year":"1961","unstructured":"Brenner, S., Jacob, F. & Meselson, M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 190, 576\u2013581 (1961).","journal-title":"Nature"},{"key":"804_CR146","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0006-291X(69)90720-7","volume":"37","author":"RE Lockard","year":"1969","unstructured":"Lockard, R. E. & Lingrel, J. B. The synthesis of mouse hemoglobin beta-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA. Biochem. Biophys. Res. Commun. 37, 204\u2013212 (1969).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"804_CR147","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/337387a0","volume":"337","author":"PL Felgner","year":"1989","unstructured":"Felgner, P. L. & Ringold, G. M. Cationic liposome-mediated transfection. Nature 337, 387\u2013388 (1989).","journal-title":"Nature"},{"key":"804_CR148","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nbt.2501","volume":"31","author":"WY Hwang","year":"2013","unstructured":"Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 31, 227\u2013229 (2013).","journal-title":"Nat. Biotechnol."},{"key":"804_CR149","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"804_CR150","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"804_CR151","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.addr.2009.03.010","volume":"61","author":"KL Aillon","year":"2009","unstructured":"Aillon, K. L., Xie, Y., El-Gendy, N., Berkland, C. J. & Forrest, M. L. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv. Drug Deliv. Rev. 61, 457\u2013466 (2009).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"804_CR152","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","volume":"244","author":"P Zhang","year":"2016","unstructured":"Zhang, P., Sun, F., Liu, S. & Jiang, S. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J. Control. Release 244, 184\u2013193 (2016).","journal-title":"J. Control. Release"},{"key":"804_CR153","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol. 36, 765\u2013771 (2018).","journal-title":"Nat. Biotechnol."},{"key":"804_CR154","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","volume":"14","author":"SQ Tsai","year":"2017","unstructured":"Tsai, S. Q. et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat. Methods 14, 607\u2013614 (2017).","journal-title":"Nat. Methods"},{"key":"804_CR155","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/cvr\/cvz250","volume":"116","author":"E Vermersch","year":"2020","unstructured":"Vermersch, E., Jouve, C. & Hulot, J. S. CRISPR\/Cas9 gene-editing strategies in cardiovascular cells. Cardiovasc. Res. 116, 894\u2013907 (2020).","journal-title":"Cardiovasc. Res."},{"key":"804_CR156","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1161\/ATVBAHA.123.319748","volume":"43","author":"MN Whittaker","year":"2023","unstructured":"Whittaker, M. N. et al. Epigenome editing durability varies widely across cardiovascular disease target genes. Arterioscler. Thromb. Vasc. Biol. 43, 2075\u20132077 (2023).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"804_CR157","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160\u20131165 (2016).","journal-title":"Science"},{"key":"804_CR158","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","volume":"32","author":"J Gust","year":"2018","unstructured":"Gust, J., Taraseviciute, A. & Turtle, C. J. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 32, 1091\u20131101 (2018).","journal-title":"CNS Drugs"},{"key":"804_CR159","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112\u2013120 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"804_CR160","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cytogfr.2025.04.002","volume":"83","author":"A Wu","year":"2025","unstructured":"Wu, A. et al. Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement. Cytokine Growth Factor Rev. 83, 66\u201376 (2025).","journal-title":"Cytokine Growth Factor Rev."},{"key":"804_CR161","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","volume":"372","author":"S Soroudi","year":"2024","unstructured":"Soroudi, S., Jaafari, M. R. & Arabi, L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy. J. Control. Release 372, 113\u2013140 (2024).","journal-title":"J. Control. Release"},{"key":"804_CR162","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1039\/c2cs15344k","volume":"41","author":"N Kamaly","year":"2012","unstructured":"Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O. C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41, 2971\u20133010 (2012).","journal-title":"Chem. Soc. Rev."},{"key":"804_CR163","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41578-022-00458-5","volume":"7","author":"ER Brannon","year":"2022","unstructured":"Brannon, E. R. et al. Polymeric particle-based therapies for acute inflammatory diseases. Nat. Rev. Mater. 7, 796\u2013813 (2022).","journal-title":"Nat. Rev. Mater."},{"key":"804_CR164","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jconrel.2022.04.046","volume":"347","author":"J Lai","year":"2022","unstructured":"Lai, J., Huang, C., Guo, Y. & Rao, L. Engineered extracellular vesicles and their mimics in cardiovascular diseases. J. Control. Release 347, 27\u201343 (2022).","journal-title":"J. Control. Release"},{"key":"804_CR165","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s43587-025-00895-1","volume":"5","author":"S Chen","year":"2025","unstructured":"Chen, S. et al. Using RNA therapeutics to promote healthy aging. Nat. Aging 5, 968\u2013983 (2025).","journal-title":"Nat. Aging"},{"key":"804_CR166","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-020-0389-5","volume":"17","author":"RC de Abreu","year":"2020","unstructured":"de Abreu, R. C. et al. Native and bioengineered extracellular vesicles for cardiovascular therapeutics. Nat. Rev. Cardiol. 17, 685\u2013697 (2020).","journal-title":"Nat. Rev. Cardiol."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00804-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00804-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00804-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:01:51Z","timestamp":1776711711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00804-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":166,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00804-8","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.T. receives consulting and lecturing fees, serves on the scientific advisory boards and conducts research at Harvard Medical School\/Brigham and Women\u2019s Hospital for Novo Nordisk and Henlius USA. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}